<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04802265</url>
  </required_header>
  <id_info>
    <org_study_id>RBHP 2021 SILLAIRE</org_study_id>
    <secondary_id>2021-A00071-40</secondary_id>
    <nct_id>NCT04802265</nct_id>
  </id_info>
  <brief_title>EpiRetinal Membrane Peeling and Internal Limiting Membrane</brief_title>
  <acronym>ERMP&amp;ILM</acronym>
  <official_title>To Compare Anatomical and Functionnal Outcomes in Patients Undergoing Epiretinal Membrane Surgery With and Without Internal Limiting Membrane Peeling</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study and compare visual acuity in patients undergoing removal of the epiretinal membrane&#xD;
      with and without the removal of the internal limiting membrane at baseline versus 6 month.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective cohort study includes 2 arms : with and without internal limiting membrane&#xD;
      (ILM) peeling.&#xD;
&#xD;
      Each patient undergo the same procedure : first of all pars plana vitrectomy, then internal&#xD;
      limiting membrane peeling is performed and facilitated by the use of dye, which aids in&#xD;
      better visualization of the ILM.&#xD;
&#xD;
      If the ILM is removed in same time : the patient is ranked in the &quot;ILM peeling&quot; group If the&#xD;
      ILM is not removed : the patient is ranked in the &quot;non ILM peeling&quot; group.&#xD;
&#xD;
      If the ILM is partially removed, the patient is not enrolled.&#xD;
&#xD;
      The outcomes are recorded for 6 months : at baseline, day 15, 1, 3 and 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2021</start_date>
  <completion_date type="Anticipated">November 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected visual acuity (BCVA) (metric : LogMAR)</measure>
    <time_frame>prior to surgery</time_frame>
    <description>BCVA is measured at each medical appointment. Monoyer Scale is used and results are converted in LogMAR scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Best corrected visual acuity (BCVA) (metric : LogMAR)</measure>
    <time_frame>Day 180</time_frame>
    <description>BCVA is measured at each medical appointment. Monoyer Scale is used and results are converted in LogMAR scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BCVA at day 15, 1, 3 month.</measure>
    <time_frame>Day 15, Day 30, Day 90</time_frame>
    <description>BCVA is measured at each medical appointment. Monoyer Scale is used and. Resulats are converted in LogMAR scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>near visual acuity measured at baseline, day 15, 1, 3 and 6 month</measure>
    <time_frame>Day 180</time_frame>
    <description>near visual acuity is measured at each medical appointment using Parinaud Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>central retinal thickness (CRT)</measure>
    <time_frame>Day 180</time_frame>
    <description>CRT is measured on optical coherence tomography (OCT) at baseline, day 15, 1 , 3 and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peeling initiation retinal thickness</measure>
    <time_frame>Day 180</time_frame>
    <description>to evaluate the damage due to the membrane gripping during the peeling initiation, retinal thickness is performed at this location by OCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10° visual field</measure>
    <time_frame>Day 180</time_frame>
    <description>a 10° Visual Field is performed at baseline, 1 month and 6 month</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Epiretinal Membrane</condition>
  <condition>Macular Pucker</condition>
  <condition>Internal Limiting Membrane</condition>
  <arm_group>
    <arm_group_label>ILM peeling</arm_group_label>
    <description>ILM is peeled during epiretinal membrane surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>without ILM peeling</arm_group_label>
    <description>ILM is not peeled during epiretinal membrane surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Epiretinal membrane surgery</intervention_name>
    <description>The surgery consists of a 23 or 25-gauge pars plana vitrectomy (PPV). The surgery was performed peri-bulbar anesthesia and could be combined with phacoemulsification.&#xD;
An intraocular dye is used to well visualized and facilitate ERM peeling. The ILM is not actively peeled. A search for iatrogenic breaks is performed towards the end of the procedure. Areas suspicious for breaks are treated with cryotherapy or peripheral endolaser.</description>
    <arm_group_label>ILM peeling</arm_group_label>
    <arm_group_label>without ILM peeling</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        adult diagnosed for epiretinal surgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult up to 18 years old,&#xD;
&#xD;
          -  diagnosed and treated surgically&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  proliferative diabetic retinopathy,&#xD;
&#xD;
          -  ocular trauma,&#xD;
&#xD;
          -  central veinous occlusion,&#xD;
&#xD;
          -  intra-ocular tumor, total retinal detachment,&#xD;
&#xD;
          -  central visual field loss in glaucomatous patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle Sillaire</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lise Laclautre</last_name>
    <phone>0473751195</phone>
    <email>promo_interne_drci@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Aura</state>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Isabelle SILLAIRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epiretinal membrane</keyword>
  <keyword>Epiretinal membrane peeling</keyword>
  <keyword>Macular pucker</keyword>
  <keyword>Internal limiting membrane (ILM) peeling</keyword>
  <keyword>Pars plana vitrectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epiretinal Membrane</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

